ClinicalTrials.gg
RecruitingNCT03468010Updated Mar 26, 2018

A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement)

A Phase 3 interventional study of chemoradiation and Paclitaxel, Cisplatin in Cervical Cancer, Adjuvant Chemotherapy and Radiation, sponsored by Sun Yat-sen University. Recruiting at 8 sites in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-03-26.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2018; still recruiting 8 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies testing paclitaxel in Uterine Cervical Neoplasms — 12 open to participants now, 13 under way, 8 of them phase 3. Paclitaxel · Uterine Cervical Neoplasms.

Planned enrollment
5th of 46
432 · median 65
Started
2018
with 1 other
Phase 3
16 of 47
7 open now
Primary completion
2025-03
later than 3 of 12 live
Registered
34th of 47
by date
Lead sponsor
3 of 47
Sun Yat-sen University

Among the 47 studies testing paclitaxel in Uterine Cervical Neoplasms, this one is the 5th largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2018, is one of 16 in phase 3, reaches primary completion later than 3 of the 12 other live ones, and was the 34th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

12 of the 47 studies testing paclitaxel in Uterine Cervical Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing paclitaxel in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

Cervical cancer with pelvic or para-aortic node involvement has a poor prognosis. Despite low-quality data, the routine practice to treat these patients is radiation with concurrent cisplatin. The aim of this study is to compare systemic chemotherapy with observation after radiation with concurrent cisplatin of cervical cancer ( with pelvic or para-aortic node involvement) for incidence of adverse events and local recurrence rate.

Read the detailed description
  1. Background Cervical Cancer is one of the most common malignant tumors of Chinese females. Women with evidence of para-aortic node involvement have a poor prognosis with a five-year survival rate of approximately 40 percent. Despite low-quality data, the routine practice to treat these patients is radiation with concurrent cisplatin. It is not clear whether systemic chemotherapy delivered following RT will obtain survival benefit.
  2. Objective The aim of this study is to compare systemic chemotherapy with observation after radiation with concurrent cisplatin of cervical cancer ( with pelvic or para-aortic node involvement) for incidence of adverse events, 3y-PFS and 5y-OS, .
  3. Patients

A patient will be enrolled when patient have:

  1. Pathologically diagnosed cervical cancer;
  2. pelvic or para-aortic lymph metastases, at least match one of following

    • CT or MRI scan shows pelvic or para-aortic node with a minimal axial diameter diameter ≥ 7mm in the largest plane
    • pelvic or para-aortic lymph node shows necrosis or extra capsular spread
    • PET/CT scan finds positive pelvic or para-aortic node lymph node
    • biopsy confirms lymph metastase
  3. Stage IB1-IVA diseases (FIGO system ver. 2014) without treatment before;
  4. Karnofsky Performance Scores ≥ 70;

4.Method

  1. Randomization is performed to divide the patients into the control group (Group A) and the experimental group (Group B). In Group A, observation is given after radiation with concurrent cisplatin. But in Group B, three cycles of adjuvant chemotherapy ( Paclitaxel plus Cisplatin) are administered after radiation with concurrent cisplatin. The regimen of adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.The Grade 3/4 adverse events (CTCAE criteria ver. 4.03), the 3-year progression-free survival of the 2 groups, the 5-year overall survival of the 2 groups are compared.
  2. In Group A and Group B, both the radiation method and the regimen of concurrent chemotherapy are the same.The gross tumor volume (GTVnd) is the lymph node lesion and given a dose of 60Gy. The clinical target volume (CTV) is according to the lymph drainage pathway and given a dose of 45Gy. The regimen of concurrent chemotherapy is Cisplatin 80mg/m2 once three weeks.
03

Conditions studied

  • Cervical Cancer
  • Adjuvant Chemotherapy
  • Radiation
  • Lymph Node Metastases
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosed cervical cancer;
  2. pelvic or para-aortic lymph , at least match one of following

    • CT or MRI scan shows pelvic or para-aortic node with a minimal axial diameter diameter ≥ 7mm in the largest plane
    • pelvic or para-aortic lymph node shows necrosis or extra capsular spread
    • PET/CT scan finds positive pelvic or para-aortic node lymph node
    • confirms lymph metastase
  3. Stage IB1-IVA diseases (FIGO system ver. 2014) without treatment before;
  4. Performance Scores ≥ 70;

Exclusion criteria

Exclusion Criteria:

  1. Patients with distant before or during radiotherapy
  2. Severe dysfunction of heart, lung, liver, kidney or hematopoietic system
  3. Severe neurological, mental or endocrine diseases
  4. History of other
  5. Those who are considered by the researchers unsuitable to participate -
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
432 participants (estimated)

Study arms

  • Active comparator
    The control group (Group A)

    In Group A, observation is given after chemoradiation

    Radiation: chemoradiation

  • Experimental
    The experiment group (Group B)

    in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.

    Radiation: chemoradiation · Drug: Paclitaxel, Cisplatin

Interventions

  • Radiationchemoradiation

    radiation with concurrent ciplatin

  • DrugPaclitaxel, Cisplatin

    Drug pages: PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.

06

What researchers measure

Primary outcomes

  1. 3-year progression-free survival (3y-PFS)

    Percentage of patients in a treatment group who are alive without disease get worse for a 3-year period of follow-up after the date of adjuvant chemotherapy completion

    Time frame: 3 years after the date of adjuvant chemotherapy completion

Secondary outcomes

  1. Incidence of grade 3/4 adverse event

    Incidence of patients in a treatment group who manifest a specific adverse event (such as myelosuppression) of grade 3/4. Incidence is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) criteria ver. 4.03.

    Time frame: Once a week during therapy, up to 5 years after the date of adjuvant chemotherapy completion

Other outcomes

  1. 5-year overall survival (5y-OS)

    Percentage of patients in a treatment group who are alive for a 5-year period of follow-up after the date of adjuvant chemotherapy completion

    Time frame: 5 years after the date of adjuvant chemotherapy completion

07

Study locations

1 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for Mar 2025, 84 months after the start.

Of 53 non-industry phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 80 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 107. This study's planned 84 months is close to that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2018
First posted
Mar 16, 2018
StartActual
Mar 1, 2018
Primary completionEst.
Mar 1, 2025
CompletionEst.
Mar 1, 2025
Last update
Mar 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03468010
Responsible party
Wei-jun Ye (Professor, Sun Yat-sen University) — Principal investigator
First posted
Mar 16, 2018
Start date
Mar 1, 2018
Primary completion
Mar 1, 2025 (estimated)
Completion
Mar 1, 2025 (estimated)
Last update
Mar 26, 2018

Study contacts

Wei-jun Ye, M.D
Contact
yewj@sysucc.org.cn
86-13538799871
Junyun Li, M.D
Contact
LIJUNY@sysucc.org.cn
86-18824712702
Wei-jun Ye, M.D
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Cisplatin

Start the discussion